Replies to post #231179 on Anavex Life Sciences Corp (AVXL)

[Investor2014]

If they realized that with the 10/20 mg the drug didn't work, why are they going to start with the extension.?The trial will fail and that it means that A273 won't be approved. The extension means to expend millions of $ and 0 chances of approval. They should do another trial with higher doses and placebo. and for now this is not the case.

A point that also seems to make good sense. Especially for a CEO claiming to want to fail early if at all.

[anders2211]

would it be a stretch to say the 10 & 20 mg doses in the main trial were not proving efficacious?
I don't think so..
1- The trial is blinded.
2- If they realized that with the 10/20 mg the drug didn't work, why are they going to start with the extension.?The trial will fail and that it means that A273 won't be approved. The extension means to expend millions of $ and 0 chances of approval. They should do another trial with higher doses and placebo. and for now this is not the case.

I agree with your thesis 100% and have said the same thing here a few times. The reply of some was that the they dont KNOW if the trial failed or not yet, since its blinded. My response to that is that I have yet to see a biotech company that does not know if their trial, is a success based on information coming from the trial sites. Most just know.
If patients would not want to enroll in the OLE, if patients would not feedback their improvement during the study then Anavex would not start the OLE for PDD. But of course there isno guarantees.